Barclays Forecasts Strong Price Appreciation for BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines (NASDAQ:ONC) had its price target lifted by Barclays from $415.00 to $446.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s target price suggests a potential upside of 9.59% from the stock’s previous close.

ONC has been the subject of several other research reports. Guggenheim increased their price objective on shares of BeOne Medicines from $420.00 to $430.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Zacks Research downgraded shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. TD Cowen boosted their target price on shares of BeOne Medicines from $424.00 to $454.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wells Fargo & Company upped their target price on shares of BeOne Medicines from $400.00 to $435.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Truist Financial increased their price target on shares of BeOne Medicines from $418.00 to $420.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Sixteen analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, BeOne Medicines has a consensus rating of “Moderate Buy” and an average target price of $434.79.

BeOne Medicines Stock Up 5.1%

NASDAQ ONC opened at $406.96 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40. The company has a market capitalization of $44.68 billion, a P/E ratio of 51.71 and a beta of 0.63. BeOne Medicines has a one year low of $253.95 and a one year high of $410.71. The stock has a 50 day moving average price of $363.49 and a 200-day moving average price of $326.34.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Thursday, November 5th. The company reported $3.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.34 by $1.30. BeOne Medicines had a net margin of 13.86% and a return on equity of 20.09%. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.76 billion. As a group, equities analysts predict that BeOne Medicines will post 8.99 EPS for the current fiscal year.

Insider Buying and Selling

In other news, COO Xiaobin Wu sold 280 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $380.00, for a total transaction of $106,400.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Xiaodong Wang sold 38,287 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $349.10, for a total value of $13,365,991.70. Following the sale, the insider owned 6,079 shares in the company, valued at $2,122,178.90. The trade was a 86.30% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 376,373 shares of company stock worth $134,848,154 in the last 90 days. Company insiders own 6.19% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE increased its position in BeOne Medicines by 7.0% during the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after acquiring an additional 26,441 shares during the last quarter. Baird Financial Group Inc. lifted its holdings in shares of BeOne Medicines by 5.5% in the 2nd quarter. Baird Financial Group Inc. now owns 368,978 shares of the company’s stock worth $105,148,000 after acquiring an additional 19,327 shares during the last quarter. Candriam S.C.A. lifted its holdings in shares of BeOne Medicines by 31.7% in the 1st quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock worth $77,132,000 after acquiring an additional 62,470 shares during the last quarter. First Trust Advisors LP lifted its holdings in shares of BeOne Medicines by 91.9% in the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after acquiring an additional 115,601 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of BeOne Medicines by 102.1% during the 1st quarter. Jennison Associates LLC now owns 154,465 shares of the company’s stock worth $45,871,000 after purchasing an additional 78,027 shares during the period. Institutional investors own 48.55% of the company’s stock.

Key Stories Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported Q3 EPS of $3.64, above the $2.34 consensus, and revenue of $1.89 billion, topping estimates of $1.76 billion. The company also raised its 2026 revenue guidance, supporting a stronger outlook. Q3 earnings and guidance
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. A faster review could bring a potential label expansion sooner, though approval is not guaranteed. FDA priority review
• Positive Sentiment: Several firms raised price targets while maintaining bullish ratings: RBC to $465, Citizens JMP to $463, Truist to $448, Barclays to $446, and Wells Fargo to $435. The revisions signal continued analyst confidence in BeOne’s prospects. RBC rating information Citizens JMP rating information Truist rating information Barclays rating information Wells Fargo rating information

About BeOne Medicines

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia.

Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.